What’s the current market cap for Abbott stock?

Abbott (ABT) has a market cap of $154bn as of June 18, 2026.

What is the P/E ratio for Abbott stock?

The price to earnings (P/E) ratio for Abbott (ABT) stock is 24.79 as of June 18, 2026.

Does Abbott stock pay dividends?

Yes, the Abbott (ABT) stock pays dividends to shareholders. As of June 18, 2026, the dividend rate is $2.44 and the yield is 2.85%. Abbott has a payout ratio of 66.73% on a trailing twelve-month basis.

When is the next Abbott dividend payment date?

The next Abbott (ABT) dividend payment is scheduled for August 17, 2026.

What is the beta indicator for Abbott?

Abbott (ABT) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Abbott stock | $ABT Share Price

About Abbott

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.

Ticker

$ABT

Sector

Health

Primary listing

NYSE

Employees

115,000

Headquarters

Abbott Park, United States

Website

www.abbott.com

Abbott Metrics

BasicAdvanced

$154bn

24.79

$3.57

0.65

$2.44

2.85%

What the Analysts think about Abbott

Analyst ratings (Buy, Hold, Sell) for Abbott stock.

Bulls say / Bears say

In Q1 2026, quarterly sales in Abbott’s medical devices segment grew 13.2% to $5.54 billion, fueled by strong demand for diabetes care and structural heart devices—demonstrating the underlying strength of these core businesses. (Reuters)

Abbott finalized its $21 billion acquisition of Exact Sciences on March 23, 2026, bringing in approximately $3 billion in high-margin cancer diagnostics revenue and positioning itself as a front-runner in oncology testing. (Reuters)

On February 27, 2026, the FDA approved Abbott’s next-generation CardioMEMS HERO device for pulmonary artery pressure monitoring, further expanding its remote heart failure monitoring offerings and creating stronger recurring revenue opportunities. (Reuters)

Abbott’s Nutrition segment experienced a 7.7% comparable sales drop in Q1 2026, as strategic price adjustments and reduced volumes negatively affected both infant and adult nutrition products. (TradingView News)

In February 2026, the FDA classified the recall of some FreeStyle Libre 3 and 3 Plus sensors as a Class I event—the most serious—after the devices were connected to seven deaths and 860 serious injuries caused by inaccurate glucose readings. (Reuters)

A Chicago jury awarded $53 million in damages to families who claimed Abbott failed to warn that its preterm infant formula could lead to necrotizing enterocolitis, highlighting significant litigation risk for the nutrition segment. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.

Abbott Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Abbott Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Abbott News

AllArticlesVideos

The Healthcare M&A Wave

Forbes·1 day ago

The Hormuz Reopening Trade: These 20 Large-Cap Stocks Still Haven't Caught Up To Pre-War Levels

Benzinga·3 days ago

Abbott Labs must face lawsuit over PediaSure children's growth claims

Reuters·2 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.